{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-007727","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.559249+00:00","generated_at":"2026-06-01T04:43:30.539381+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenax Therapeutics expands equity pool by 400k shares; CMO shifts to part-time","bullets":["Stockholders approved Amendment No. 1 to 2022 Stock Incentive Plan, increasing authorized shares to 400,688.","CMO Dr. Stuart Rich will work 3 days/week from June 15, 2024; annual base salary of $333,900 prorated to 60%.","Board elected; auditor Cherry Bekaert LLP ratified. Next advisory vote on exec compensation set for 2025 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-007727","json":"https://secwatch.observer/filing/0001654954-24-007727.json","markdown":"https://secwatch.observer/filing/0001654954-24-007727.md","text":"https://secwatch.observer/filing/0001654954-24-007727.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495424007727/0001654954-24-007727-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495424007727/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:43:30.539381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}